McCorvey E, Wright J T, Culbert J P, McKenney J M, Proctor J D, Annett M P
College of Pharmacy and Pharmaceutical Sciences, Florida Agricultural and Mechanical University, Miami.
Clin Pharm. 1993 Apr;12(4):300-5.
The effect of hydrochlorothiazide, propranolol, and enalapril on cognitive and motor function and quality of life (QOL) in hypertensive patients was studied. Patients > or = 55 years of age with asymptomatic essential hypertension were included in a randomized, double-blind, placebo-controlled, crossover study. Subjects discontinued their previous antihypertensive agents and started hydrochlorothiazide 25 mg, extended-release propranolol hydrochloride 120 mg, enalapril maleate 10 mg, or placebo. One capsule was taken for three days and then the dosage was doubled for the remainder of a four-week period. Subsequent crossover treatments were begun without a washout period. In each treatment phase, a battery of psychometric tests was used to assess cognitive and motor function and quality of life; all tests but one were self-administered via computer terminal. Pulse rate and blood pressure were recorded, and compliance was monitored by capsule count. Sixteen of 30 patients interviewed completed the trials; one additional patient was evaluated after receiving all treatments except hydrochlorothiazide. Mean +/- S.D. age of the subjects was 66 +/- 6.1 years; 10 were black and 7 white; 9 were men. Except for the hydrochlorothiazide group, blood pressure in the active treatment groups did not differ significantly from placebo; hydrochlorothiazide significantly reduced systolic but not diastolic blood pressure compared with placebo. Compared with placebo, hydrochlorothiazide was associated with fewer incorrect responses in a test of complex reaction time and with greater discriminant reaction time response rates; otherwise, no difference between groups was noted in cognitive or motor performance. There were no significant differences between active treatments and placebo on individual QOL measures.(ABSTRACT TRUNCATED AT 250 WORDS)
研究了氢氯噻嗪、普萘洛尔和依那普利对高血压患者认知与运动功能及生活质量(QOL)的影响。年龄≥55岁的无症状原发性高血压患者纳入一项随机、双盲、安慰剂对照的交叉研究。受试者停用之前的抗高血压药物,开始服用25mg氢氯噻嗪、120mg盐酸普萘洛尔缓释片、10mg马来酸依那普利或安慰剂。一粒胶囊服用三天,然后在接下来的四周内剂量加倍。后续交叉治疗开始时没有洗脱期。在每个治疗阶段,使用一系列心理测量测试来评估认知与运动功能及生活质量;除一项测试外,所有测试均通过计算机终端自行完成。记录脉搏率和血压,并通过胶囊计数监测依从性。接受访谈的30名患者中有16名完成了试验;另有一名患者在接受除氢氯噻嗪之外的所有治疗后进行了评估。受试者的平均年龄±标准差为66±6.1岁;10人为黑人,7人为白人;9人为男性。除氢氯噻嗪组外,活性治疗组的血压与安慰剂组相比无显著差异;与安慰剂相比,氢氯噻嗪显著降低收缩压但不降低舒张压。与安慰剂相比,氢氯噻嗪在复杂反应时间测试中错误反应较少,判别反应时间反应率较高;否则,在认知或运动表现方面未发现组间差异。在个体生活质量测量方面,活性治疗与安慰剂之间无显著差异。(摘要截断于250字)